Expertise in
12
conditions

Massimo Terzolo

Orbassano, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Orbassano, IT 

Overview

Massimo Terzolo practices practicing medicine in Orbassano, Italy.

Mr. Terzolo is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Adrenal Cancer, Adrenocortical Carcinoma, Cushing's syndrome, Hormone Replacement Therapy (HRT), and Nephrectomy.

He is actively involved in clinical research, co-authoring 180 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Orbassano, 10043, Italy
Other Locations
Turin, Italy
Rome, Italy
Brescia, 25123, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Enrollment Status: Recruiting
Publish Date: July 16, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Etoposide, Mitotane
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

180 Total Publications

Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial.
Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial.
Journal: Cancers
Published: July 06, 2026

Frequently Asked Questions about Massimo Terzolo

Is Massimo Terzolo a top-rated expert for Adrenal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Massimo Terzolo is classified as an Elite expert for Adrenal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Massimo Terzolo participate in research or clinical trials?

Yes. Massimo Terzolo has published 180 articles and abstracts on conditions like Adrenal Cancer. You can view a list of Massimo Terzolo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Terzolo's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile